Abstract
Alzheimer's disease (AD) is a multi factorial disease, related to the loss of neurons and synapses in cerebral cortex and subcortical structures, leading to degenerative changes and atrophy. Despite abundance of facts related to AD and its pathology, the only drugs used in the prevention and treatment are those from the cholinesterase inhibitors group. However, there is growing evidence that a non-classical therapeutic approach in the treatment of AD has beneficial effects. In this review we summarized recent literature data related to the non-classical drugs for the treatment of AD predominantly used in clinical testing, such as amyloid aggregation inhibitors, beta-sheet breakers, antioxidants, estrogens and immunotherapeutics.
Keywords: Amyloid aggregation inhibitors, antioxidants, beta-sheet breakers, estrogens, immunotherapeutic Abeta, neurodegeneration.
Letters in Drug Design & Discovery
Title:Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review
Volume: 12 Issue: 2
Author(s): Vladan Bajic, Biljana Spremo-Potparevic, Lada Zivkovic, Emina Sudar, Sonja Zafirovic, Milan Obradovic and Esma R. Isenovic
Affiliation:
Keywords: Amyloid aggregation inhibitors, antioxidants, beta-sheet breakers, estrogens, immunotherapeutic Abeta, neurodegeneration.
Abstract: Alzheimer's disease (AD) is a multi factorial disease, related to the loss of neurons and synapses in cerebral cortex and subcortical structures, leading to degenerative changes and atrophy. Despite abundance of facts related to AD and its pathology, the only drugs used in the prevention and treatment are those from the cholinesterase inhibitors group. However, there is growing evidence that a non-classical therapeutic approach in the treatment of AD has beneficial effects. In this review we summarized recent literature data related to the non-classical drugs for the treatment of AD predominantly used in clinical testing, such as amyloid aggregation inhibitors, beta-sheet breakers, antioxidants, estrogens and immunotherapeutics.
Export Options
About this article
Cite this article as:
Bajic Vladan, Spremo-Potparevic Biljana, Zivkovic Lada, Sudar Emina, Zafirovic Sonja, Obradovic Milan and Isenovic R. Esma, Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review, Letters in Drug Design & Discovery 2015; 12 (2) . https://dx.doi.org/10.2174/1570180811666140909010803
DOI https://dx.doi.org/10.2174/1570180811666140909010803 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Viral Agents in Neurodegenerative Disorders: New Paradigm for Targeting Alzheimer’s Disease
Recent Patents on Anti-Infective Drug Discovery Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
CNS & Neurological Disorders - Drug Targets Radiolabeled Organism-Specific Antibodies for Diagnosis and Therapy of Infections
Current Medical Imaging Antiproliferative and Antifungal Activities of 1,3-diarylpropane-1,3-diones Commonly used as Sunscreen Agents
Letters in Drug Design & Discovery Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Novel Aβ Immunogens: Is Shorter Better?
Current Alzheimer Research Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases
Current Pharmaceutical Design Cognition-Enhancing Drugs in Mild Cognitive Impairment (MCI) and Alzheimers Disease (AD): An Update [1]
Medicinal Chemistry Reviews - Online (Discontinued) Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy
Current Topics in Medicinal Chemistry Research Progress of Mechanisms of Ceftriaxone Associated Nephrolithiasis
Mini-Reviews in Medicinal Chemistry Current Status of Anti-Picornavirus Therapies
Current Pharmaceutical Design Therapeutic Perspectives in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research
Current Medicinal Chemistry Management and Treatment of Dengue and Chikungunya - Natural Products to the Rescue
Combinatorial Chemistry & High Throughput Screening Innovative Methodology in the Discovery of Novel Drug Targets in the Free-Living Amoebae
Current Drug Targets Concomitant Gene Mutations of MBL and CYBB in Chronic Granulomatous Disease: Implications for Host Defense
Inflammation & Allergy - Drug Targets (Discontinued) Current Experimental Therapy for Alzheimers Disease
Current Neuropharmacology Editorial [Hot Topic:Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CNS & Neurological Disorders - Drug Targets